SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The filing discloses the dismissal of Deloitte & Touche LLP as the Company's independent registered public accounting firm effective June 30, 2026, and the concurrent engagement of Grant Thornton, LLP as the new auditor. This is a classic auditor change under Item 4.01, with no disagreements or reportable events noted, indicating a routine competitive selection process rather than an audit failure or dispute.
View raw filing on EDGAR →The filing discloses a notice of redemption for $325 million in 6.125% Senior Notes due 2028, conditioned on receipt of net proceeds from a delayed draw term loan facility. While this is technically a redemption (retirement) of existing debt rather than issuance of new debt, the operative financial event is the creation of a new direct financial obligation via the delayed draw term loan to fund the redemption. However, the prose centers on the redemption itself, which is not a standard debt_issuance event type; this could also be classified as financial_other since it involves debt restructuring/refinancing rather than a clean new debt issuance.
View raw filing on EDGAR →UGI Energy Services entered into a Fourth Amendment to its Credit Agreement on June 30, 2026, modifying the Applicable Rate for SOFR and base rate loans, which materially affects the company's borrowing costs and direct financial obligations.
View raw filing on EDGAR →Iridium Communications completed its acquisition of the remaining 61% equity interests in Aireon Holdings LLC on July 2, 2026, for approximately $366.7 million, resulting in full ownership of Aireon. The acquisition combines Aireon's space-based ADS-B air traffic surveillance system with Iridium's satellite communications network and positioning, navigation, and timing capabilities, materially expanding Iridium's role in the aviation ecosystem.
View raw filing on EDGAR →The Compensation Committee approved cash retention awards for two named executive officers—Vincent J. O'Neill (CFO) and Kathleen A. Morgan (Chief Legal Officer)—totaling approximately $1.28 million, with tranches tied to the pending Rocket Lab merger closing and specific vesting conditions and severance provisions.
View raw filing on EDGAR →Golub Capital Private Credit Fund entered into a Fourth Amendment to its unsecured revolving credit agreement on July 2, 2026, extending the maturity date to July 3, 2029. This amendment materially modifies the terms of the registrant's existing credit facility, extending its maturity and affecting the fund's liquidity and capital structure.
View raw filing on EDGAR →SCHMID Group announced entry into an investment agreement on July 7, 2026 to issue and sell $20 million in senior convertible notes in a private placement. The Notes are convertible into ordinary shares at specified conversion prices, materially affecting shareholder equity and voting power through the dilutive conversion feature.
View raw filing on EDGAR →SCHMID Group received a repeat order exceeding EUR 37 million from a major Chinese customer for advanced HDI-ML and mSAP production equipment, demonstrating strong demand momentum in AI-related electronics manufacturing and contributing to the company's revised year-to-date order intake guidance of EUR 81.7 million.
View raw filing on EDGAR →Ivanhoe Electric entered into an Amended and Restated Shareholders Agreement on July 7, 2026, governing a 50/50 joint venture with Saudi Arabian Mining Company (Maaden) for mineral exploration in Saudi Arabia. The agreement materially modifies the prior 2023 agreement by extending the exploration term to ten years (through July 6, 2033), expanding the Joint Venture's ability to acquire licenses directly, and restructuring governance and operational authority. This constitutes a material definitive contract modification affecting the Company's strategic partnership and exploration rights in a significant geographic region, warranting disclosure under Item 1.01.
View raw filing on EDGAR →MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (plus up to $5 million in contingent consideration) effective June 30, 2026. The transaction involves the transfer of approximately 140 employees and two manufacturing facilities, representing a material disposition of a significant business segment and a strategic shift toward a clinical-stage company focused on internal pipeline development.
View raw filing on EDGAR →This exhibit is a formal Remuneration Policy for Administrators of Itaú Unibanco Holding S.A., approved by the Board of Directors on 06/25/2026. It comprehensively discloses compensatory arrangements for directors and officers, including fixed and variable remuneration structures, equity-based compensation requirements (minimum 70% of variable remuneration in shares deferred over three years), malus and clawback mechanisms, and ESG-linked performance criteria. The policy also incorporates a Clawback Policy compliant with NYSE Rule 10D-1 and SEC Section 10D. This is a material disclosure of executive compensation governance and structure that would affect investor assessment of the company's compensation practices and risk management alignment.
View raw filing on EDGAR →This announcement discloses a board-approved one-for-fifteen reverse stock split effective July 9, 2026, reducing outstanding shares from approximately 8.7 million to 0.6 million. While a reverse split is a governance/capital structure action rather than a discrete material event in the traditional sense, it is material to investors as it affects share count, trading price, and potential delisting-risk implications (reverse splits are often undertaken to maintain listing standards). The disclosure is clearly governance-related but does not fit the specific named categories (exec appointment/departure, compensation, shareholder vote results, etc.), making `governance_other` the most appropriate classification.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the prose centers on Slutsky's promotion to a senior operational role with expanded responsibilities overseeing legal, compliance, technology, trading, administration, and human resources. The detailed biographical and compensation information provided for Slutsky (age, education, tenure, salary eligibility, post-employment obligations) emphasizes the appointment as the principal disclosed action, making this an exec_appointment event.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the filing's primary focus and detailed disclosure center on Slutsky's appointment to the COO role, including his background, responsibilities, and compensation terms. The appointment of a COO to lead critical operational functions (legal, compliance, technology, trading services, administration, HR) is material to investors' assessment of the fund's management and governance.
View raw filing on EDGAR →Campbell Fund Trust sold unregistered Units of Beneficial Interest totaling approximately $6.77 million across three series (A, D, W) on June 30, 2026, pursuant to Section 4(2) and Regulation D exemptions. This is a private placement of equity securities meeting the definition of dilutive_issuance, and the aggregate consideration of nearly $7 million is material to a fund trust registrant.
View raw filing on EDGAR →The filing discloses a Securities Purchase Agreement under which EEME will purchase $1,000,000 of DevvStream's common shares at $0.28683 per share, resulting in issuance of 3,486,386 common shares. This is a private placement of equity securities representing significant dilution to existing shareholders. While the Item 3.01 caption references delisting risk, the actual prose describes a capital raise through equity issuance rather than a delisting notice or listing failure, making dilutive_issuance the more precise classification.
View raw filing on EDGAR →This press release announces results of a germanium evaluation program at Titan's Empire State Mines property, confirming district-wide germanium enrichment across multiple ore bodies and tailings facilities. The disclosure is operational and strategic in nature—it reports on exploration/characterization work and identifies priority targets for further development (Mud Pond Main and Edwards tailings), with next steps including deportment studies and recovery test work. While not a discrete M&A, financing, or governance event, the confirmation of a recoverable critical mineral by-product at current strong pricing (~$6,000/kg) and the company's positioning in the domestic critical minerals supply chain would materially affect a reasonable investor's assessment of the asset's value and the company's strategic direction.
View raw filing on EDGAR →This press release discloses material operational and development progress on the Corani Silver Project, including workforce expansion to 300+ team members, appointment of a new project management leader (Carlos Ojeda), and advancement of key construction milestones (camp facilities, earthworks, road construction, substation). While not a discrete event like an acquisition or executive appointment, the disclosure of substantial project development progress on the company's flagship asset—described as "the largest silver deposit in development globally"—would materially affect a reasonable investor's assessment of the registrant's operational trajectory and capital deployment.
View raw filing on EDGAR →This press release announces the commencement of Fury's 2026 drilling program at the Committee Bay project in Nunavut, comprising approximately 5,000 metres of diamond drilling focused on resource growth at Three Bluffs and Antler. The disclosure details specific exploration activities, drilling targets, and historical mineralization results. This is a material operational/strategic milestone for an exploration-stage company advancing its gold portfolio, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, or other discrete event types). It represents a significant exploration program update that would inform investor assessment of the company's project advancement and value creation strategy.
View raw filing on EDGAR →Anfield announced receipt of ATF blasting permits for its Utah and Colorado mines, enabling transition from development to active underground mining operations at Velvet-Wood and positioning JD-8 for imminent production. This is a material operational and regulatory milestone that advances the company's core mining development strategy and removes a critical permitting barrier to production, but does not fit the specific event categories (M&A, earnings, executive changes, impairments, etc.); it is best classified as a material operational milestone.
View raw filing on EDGAR →This press release announces a material operational and strategic milestone: submission of a Detailed Project Description (DPD) to the BC Environmental Assessment Office for the Yellowhead copper project, advancing it through the provincial EA process. The disclosure includes an economic impact study projecting $47 billion in total economic output and positioning Yellowhead as Canada's second-largest copper producer. While the project remains in the permitting phase (not yet approved), the advancement through EA and the scale of projected production (178 million pounds annually over 25 years) would materially affect a reasonable investor's assessment of the company's future production capacity and growth strategy. This is an operational/strategic milestone rather than a discrete event type (not M&A, not a financial result, not a governance change), making operational_other the most appropriate classification.
View raw filing on EDGAR →The filing discloses an announcement of the release date for second quarter 2026 financial results, scheduled for July 30, 2026. The press release explicitly states the Company "plans to release its results for the second quarter ended June 30, 2026" and will provide a supplemental investor presentation and pre-recorded audio webcast with management commentary. This is a standard earnings announcement that would materially affect investor assessment of the registrant's financial performance.
View raw filing on EDGAR →Equinox Gold announced the sale of 8,713,000 common shares of Versamet Royalties Corporation for C$130 million gross proceeds, reducing its ownership stake from 10.7% to 2.7%. This is a material disposition of a significant investment asset that generates substantial cash proceeds and materially alters the company's ownership position and contractual rights (termination of right of first offer and investor rights agreement). While not a core business acquisition or divestiture, it is a material financial transaction affecting the registrant's asset base and capital position.
View raw filing on EDGAR →The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be "invaluable as we execute on several key upcoming milestones," indicating material governance strengthening at a pivotal stage for the company.
View raw filing on EDGAR →The 6-K announces that Tower Semiconductor "will issue its second quarter 2026 earnings release on Tuesday, August 4, 2026" and will hold a conference call to discuss Q2 2026 financial results and Q3 2026 guidance. Although the actual earnings release is scheduled for future delivery (August 4), the announcement itself is a disclosure of material financial results and guidance, which is the substance of an earnings event. This is material to investors assessing the registrant's financial performance and outlook.
View raw filing on EDGAR →Gilat announced receipt of $11 million in orders from the U.S. Department of War for field services and custom SATCOM terminals, with deliveries expected over the next 12 months. This is a material contract award that demonstrates significant defense customer demand and reinforces the company's strategic position in mission-critical defense connectivity. While not a discrete M&A transaction or financial restatement, the award represents a material operational and commercial milestone that would affect a reasonable investor's assessment of the company's growth trajectory and defense-sector revenue prospects.
View raw filing on EDGAR →Lifeward entered into a Securities Purchase Agreement on June 30, 2026, closing July 6, 2026, issuing $5.58 million in senior secured convertible notes with an additional $5.58 million contingent on performance milestones or stock price targets. The notes are convertible into ordinary shares at $5.40 per share, accrue interest at 8.0% (rising to 15.0% on default), and mature in three years.
View raw filing on EDGAR →VSee Health issued two convertible notes totaling approximately $575,550 in principal (ClearThink Note for $280,000 and Vanquish Note for $295,550), each convertible into common stock at discounted prices (85% and 75% of lowest closing price, respectively) with minimal beneficial ownership caps of 4.99%. This PIPE-like financing structure creates substantial dilution risk for existing shareholders.
View raw filing on EDGAR →Z Squared Inc. entered into an at-the-market (ATM) sales agreement with Roth Capital Partners to offer and sell up to $300 million in common stock shares under an effective shelf registration statement. This dilutive equity issuance is material to investors assessing capital structure and shareholder dilution.
View raw filing on EDGAR →This Item 8.01 disclosure reports the consummation of a blank-check company's initial public offering on June 26, 2026, generating $275 million in gross proceeds from the sale of 27.5 million units, plus a concurrent private placement of warrants generating $5 million. While the IPO itself is a capital-raising event, it does not fit neatly into the standard taxonomy: it is not an earnings release, M&A activity, debt issuance, or dilutive equity issuance in the traditional sense (the company is newly public and has no prior operations). The disclosure is material to investors as it establishes the company's capitalization and trust-account structure for a future business combination, but the event type is ambiguous—it is primarily a financial/capital event for a SPAC, which does not map cleanly to any single category.
View raw filing on EDGAR →The disclosure centers on the appointment of Karen Fascenda as Chief Human Resources Officer effective July 6, 2026, succeeding Novelette Murray who retired the same day. While both a departure and appointment occur, the press release and Item 8.01 disclosure emphasize the appointment of the new CHRO with detailed background on her qualifications and experience, making exec_appointment the principal event. The CHRO is a named executive officer role, and the appointment of a successor to a C-suite position is material to investors assessing leadership continuity and human capital strategy.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Choi, Hoe-Yong as a non-standing director of KEPCO, effective July 7, 2026, for a two-year term, replacing former director Mr. Kang, Hoon. This is a clear executive/director appointment event. While non-standing directors may have limited operational authority, director appointments at a major utility company are material to investors' assessment of governance and board composition.
View raw filing on EDGAR →The filing discloses that the HSR Waiting Period for the proposed merger between Taylor Morrison and Berkshire Hathaway expired on July 6, 2026, removing a key closing condition. This represents material progress toward completion of a change-of-control transaction that was previously disclosed on May 31, 2026. The merger remains subject to shareholder approval and other regulatory approvals, but the HSR clearance is a significant milestone in the M&A process that would materially affect investor assessment of transaction likelihood and timing.
View raw filing on EDGAR →Douglas Hudson, a Class II board member, resigned from the Board and the Nominating and Corporate Governance Committee effective June 30, 2026. The disclosure explicitly states the resignation was not due to disagreement, indicating a routine departure. Board composition changes are material to investors as they affect governance and oversight structure.
View raw filing on EDGAR →SAB Biotherapeutics announced that Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study evaluating SAB-142 in Stage 3 Type 1 Diabetes patients. This represents a material operational and clinical development milestone—the expansion of the company's clinical program into a new patient population (100 days to 2 years post-diagnosis) with external funding support. While the disclosure is operational in nature (a clinical trial advancement), it does not fit neatly into the specific operational categories (no material contract, partnership, or regulatory milestone language), making operational_other the most appropriate classification.
View raw filing on EDGAR →The filing discloses an unregistered sale of common shares totaling $2,302,688 (approximately 92,900 shares at $24.79 per share) pursuant to subscription agreements and capital calls. The sale was conducted under Section 4(a)(2), Regulation D, and/or Regulation S exemptions from Securities Act registration. This is a classic dilutive equity issuance to investors relying on accredited investor or non-U.S. person exemptions, directly matching the dilutive_issuance category.
View raw filing on EDGAR →The disclosure announces a 1:200 reverse stock split approved by the board and effective July 12, 2026. While reverse stock splits are capital structure events that affect share count and pricing, they do not fit neatly into the specific taxonomy categories (not M&A, not a debt/equity issuance in the traditional sense, not a dividend, not a delisting notice). The event is material to investors as it materially alters the share structure and trading mechanics, but the domain is financial/capital structure rather than a named event type, warranting classification as other_material.
View raw filing on EDGAR →This press release announces positive phase 3 clinical trial results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease, with the drug meeting its primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to submit regulatory data for a label extension in the US in H2 2026. This is a material clinical milestone and regulatory development for a rare disease therapeutic, but it does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the product pipeline that would affect investor assessment of the company's development progress and commercial prospects.
View raw filing on EDGAR →Olaplex completed a merger on July 7, 2026, in which common shareholders received $2.06 per share in cash consideration and the company became a wholly owned subsidiary of the acquirer. The transaction had an equity value of approximately $1.4 billion, involved repayment of $357.6 million in outstanding debt and termination of the Credit Agreement, and resulted in delisting from Nasdaq and termination of SEC registration.
View raw filing on EDGAR →Semnur entered into a binding term sheet with iHolding Group LLP for a $100 million strategic investment involving the issuance of approximately 10 million shares of common stock at $10.00 per share. The transaction, subject to customary closing conditions including due diligence, definitive agreements, and stockholder approval, represents a material dilutive equity issuance that would significantly increase share count and dilute existing shareholders.
View raw filing on EDGAR →The 6-K furnishes forms of multiple senior callable notes due 2032–2047 with varying rates (floating and fixed-to-floating), indicating a material debt issuance program. The exhibits include legal opinions and tax opinions required for debt offerings, and the filing incorporates the disclosure into the registrant's Form F-3 registration statement, confirming this is a debt capital-raising event material to investors.
View raw filing on EDGAR →The Company sold 27,194 Class D Common Shares for $750,000 gross proceeds on July 1, 2026, pursuant to a continuous private placement offering of up to $2.165 billion in common shares under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance that dilutes existing shareholders and is material to investors assessing capital structure and ownership changes.
View raw filing on EDGAR →The disclosure announces FDA accelerated approval of TRUTAKNA (atacicept-vymj) for a specific indication in primary immunoglobulin A nephropathy. This is a material regulatory milestone and product approval event that would significantly affect investor assessment of the company's pipeline and commercial prospects, but does not fit the specific categories of earnings release, M&A, impairment, or other named event types. It is clearly operational/strategic in nature.
View raw filing on EDGAR →The filing discloses the Board's determination on June 30, 2026 to appoint Gregory R. Allen to fill an open vacancy on the Board of Directors, with his first meeting scheduled for September 29, 2026. While the disclosure includes standard board compensation details and related-party transaction disclosures, the principal action is the appointment of a director to the Board. This is a material governance event affecting the composition of the registrant's board.
View raw filing on EDGAR →The Twenty-Seventh Amendment modifies the Company's existing Senior Secured Credit Agreement by deferring a $840,000 quarterly amortization payment and converting $210,000 in accrued interest to payment-in-kind status. While this is technically an amendment to existing debt rather than a new issuance, it creates or modifies direct financial obligations under Item 2.03. The amendment also involves a dilutive equity issuance (2,980,903 shares, ~1.5% of fully-diluted ownership) as consideration, and leaves approximately $93.2 million due at maturity on December 20, 2026, signaling material refinancing risk.
View raw filing on EDGAR →The Company issued 11,698 shares of Class X-1 common stock to accredited investors in a private placement for $275,000 aggregate proceeds, exempt from registration under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance disclosed under Item 3.02, representing dilution to existing shareholders and capital raised by the registrant.
View raw filing on EDGAR →The filing discloses an unregistered sale of 1,280,957 common shares for approximately $26.42 million under Section 4(a)(2) and Regulation D Rule 506, which is a classic private placement. This is a dilutive equity issuance that raises capital and increases share count, material to investors assessing the registrant's capitalization and ownership structure.
View raw filing on EDGAR →Andrew Gelb and Srini Krish were appointed as interim leaders of Fiserv's Financial Solutions business effective July 7, 2026, following the departure of the President.
View raw filing on EDGAR →The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.
View raw filing on EDGAR →The filing discloses the appointment of Evgeny Zaytsev, M.D., Ph.D. as a Class I director effective immediately, with the Board increasing from seven to eight directors. While the section also mentions Fred Middleton's retirement, the principal disclosed action centers on the new director appointment. The appointment includes standard director compensation (annual cash retainer of $40,000 and a 20,000-share option grant vesting over three years), which is material to investors assessing board composition and governance.
View raw filing on EDGAR →